{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:49:21Z","timestamp":1790534961102,"version":"4.1.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.24406","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T15:49:05Z","timestamp":1605023345000},"page":"e2024406","source":"Crossref","is-referenced-by-count":95,"title":["Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016"],"prefix":"10.1001","volume":"3","author":[{"given":"Aviv","family":"Ladanie","sequence":"first","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Swiss Tropical and Public Health Institute, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Speich","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Naudet","sequence":"additional","affiliation":[{"name":"Universite de Rennes, CHU Rennes, Inserm, CIC 1414\u2013Centre d\u2019Investigation Clinique de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago V.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada"},{"name":"Department of Health Sciences, College of Medicine, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Herbrand","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital and University of Basel, Basel, Switzerland"},{"name":"St Clara Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Martin-Liberal","sequence":"additional","affiliation":[{"name":"Melanoma, Sarcoma and GU Tumors Unit, Catalan Institute of Oncology Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmid","sequence":"additional","affiliation":[{"name":"St Clara Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ewald","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Swiss Tropical and Public Health Institute, Basel, Switzerland"},{"name":"University Medical Library, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P. A.","family":"Ioannidis","sequence":"additional","affiliation":[{"name":"Meta-Research Innovation Center at Stanford, Stanford University, Stanford, California"},{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California"},{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California"},{"name":"Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California"},{"name":"Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner C.","family":"Bucher","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kasenda","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"},{"name":"Medical Oncology, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars G.","family":"Hemkens","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"issue":"4","key":"zoi200806r1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"zoi200806r2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi200806r3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration.","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi200806r4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines.","volume":"3","author":"Salas-Vega","year":"2017","journal-title":"JAMA Oncol"},{"key":"zoi200806r5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.05.033","article-title":"Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.","volume":"114","author":"Ladanie","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"zoi200806r6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi200806r7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/1468-0009.12261","article-title":"Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval.","volume":"95","author":"Naci","year":"2017","journal-title":"Milbank Q"},{"issue":"7","key":"zoi200806r8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration.","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"key":"zoi200806r9","doi-asserted-by":"publisher","first-page":"j1680","DOI":"10.1136\/bmj.j1680","article-title":"Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.","volume":"357","author":"Pease","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"zoi200806r10","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"zoi200806r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.03.011","article-title":"Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.","volume":"56","author":"Barnes","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"zoi200806r12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrclinonc.2017.18","article-title":"Approvals in 2016: questioning the clinical benefit of anticancer therapies.","volume":"14","author":"Booth","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"zoi200806r13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/jnci\/djx232","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration.","volume":"110","author":"Tibau","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"zoi200806r14","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics\u2014the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley lecture.","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"10","key":"zoi200806r15","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.v123.10","article-title":"Meaningful endpoints for therapies approved for hematologic malignancies.","volume":"123","author":"Smith","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"zoi200806r16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s13063-018-2877-z","article-title":"The comparative effectiveness of innovative treatments for cancer (CEIT-Cancer) project: rationale and design of the database and the collection of evidence available at approval of novel drugs.","volume":"19","author":"Ladanie","year":"2018","journal-title":"Trials"},{"key":"zoi200806r17","doi-asserted-by":"publisher","first-page":"k2815","DOI":"10.1136\/bmj.k2815","article-title":"How to use FDA drug approval documents for evidence syntheses.","volume":"362","author":"Ladanie","year":"2018","journal-title":"BMJ"},{"issue":"9596","key":"zoi200806r18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"zoi200806r21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"zoi200806r22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"10043","key":"zoi200806r25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"zoi200806r28","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi200806r29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"4","key":"zoi200806r30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi200806r31","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"zoi200806r32","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"zoi200806r33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jama.2018.7619","article-title":"Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation.","volume":"320","author":"Puthumana","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"zoi200806r34","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/EDE.0b013e31818131e7","article-title":"Why most discovered true associations are inflated.","volume":"19","author":"Ioannidis","year":"2008","journal-title":"Epidemiology"},{"issue":"16","key":"zoi200806r35","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"9911","key":"zoi200806r36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"zoi200806r37","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9944","key":"zoi200806r38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non\u2013small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"zoi200806r39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line Folfiri in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi200806r40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased a-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"zoi200806r41","doi-asserted-by":"publisher","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"zoi200806r42","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future.","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7658","key":"zoi200806r43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/bmj.a117","article-title":"Reasons or excuses for avoiding meta-analysis in forest plots.","volume":"336","author":"Ioannidis","year":"2008","journal-title":"BMJ"},{"key":"zoi200806r44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jclinepi.2018.01.011","article-title":"Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval.","volume":"98","author":"Djulbegovic","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"zoi200806r19","unstructured":"US Food and Drug Administration. Drugs@FDA: US Department of Health and Human Services. Accessed November 29, 2019. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"zoi200806r20","unstructured":"Miller? BW, Przepiorka? D; Center for Drug Evaluation and Research. Medical review: idelalisib (trade name Zydelig). US Food and Drug Administration; May 9, 2014. Accessed March 1, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205858Orig1s000MedR.pdf"},{"key":"zoi200806r23","unstructured":"Designation of Drugs for Rare Diseases or Conditions, 21 USC \u00a7360bb (1983). Accessed March 1, 2020. https:\/\/www.law.cornell.edu\/uscode\/text\/21\/360bb?"},{"key":"zoi200806r24","unstructured":"Accelerated Approval Program. US Food and Drug Administration. Published March 10, 2016. Accessed March 1, 2020. https:\/\/www.fda.gov\/drugs\/information-healthcare-professionals-drugs\/accelerated-approval-program"},{"key":"zoi200806r26","unstructured":"The ASCO Post staff. Results reported from the phase III ANNOUNCE trial of olaratumab in soft-tissue sarcoma. The ASCO Post. January 28, 2019. Accessed October 5, 2020. https:\/\/ascopost.com\/News\/59688"},{"key":"zoi200806r27","unstructured":"Lilly to establish an access program for patients as it prepares to withdraw Lartruvo from the global market. News release. Eli Lilly and Company. April 25, 2019. Accessed August 25, 2020. http:\/\/lilly.mediaroom.com\/index.php?s=9042&item=137894"},{"key":"zoi200806r45","unstructured":"Bichell? RE. If a new cancer drug is hailed as a breakthrough, odds are it's not. National Public Radio. October 29, 2015. Accessed October 5, 2020. https:\/\/www.npr.org\/sections\/health-shots\/2015\/10\/29\/452610534\/if-a-new-cancer-drugs-hailed-as-a-breakthrough-odds-are-its-not"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2772736\/ladanie_2020_oi_200806_1604346461.57057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T15:49:18Z","timestamp":1605023358000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2772736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.24406","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}